Skip to content
OpenCapital
Get started

Aptevo Therapeutics APVO Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$40.11Miss by $2.52
EPS estimate-$37.59

Next report

Aug 10, 2026 (In 1 week)
EPS estimate-$6.02

Versus estimates

Diluted EPS

Q1 2026-$6.41Miss by $0.81Q4 2025$1,684.47Beat by $1,692.56
Q3 2025-$40.11Miss by $2.52
Q2 2025-$151.08Miss by $150.63Q1 2025-$1,579.14Miss by $64.75Q4 2024-$82.37Miss by $74.62

Ask the moment Aptevo Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Aptevo Therapeutics report Q3 2025 earnings?
Aptevo Therapeutics (APVO) reported Q3 2025 earnings on November 6, 2025 before market open.
What were Aptevo Therapeutics's Q3 2025 revenue and EPS?
Aptevo Therapeutics reported eps of $-40.11 for Q3 2025.
Did Aptevo Therapeutics beat estimates in Q3 2025?
EPS missed the consensus estimate of $-37.59 by $2.52.
How did Aptevo Therapeutics's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 99.4% from $-6255.86.
Where can I find Aptevo Therapeutics's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-269470) and the 10-Q periodic report (0001193125-25-269598) directly on SEC EDGAR. The filing index links above go to sec.gov.